View Item 

Show simple item record

Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors
dc.contributor.authorStolz, Andrew
dc.contributor.authorNavarro, Victor
dc.contributor.authorHayashi, Paul H.
dc.contributor.authorFontana, Robert J.
dc.contributor.authorBarnhart, Huiman X.
dc.contributor.authorGu, Jiezhun
dc.contributor.authorChalasani, Naga P.
dc.contributor.authorVega, Maricruz M.
dc.contributor.authorBonkovsky, Herbert L.
dc.contributor.authorSeeff, Leonard B.
dc.contributor.authorSerrano, Jose
dc.contributor.authorAvula, Bharathi
dc.contributor.authorKhan, Ikhlas A.
dc.contributor.authorCirulli, Elizabeth T.
dc.contributor.authorKleiner, David E.
dc.contributor.authorHoofnagle, Jay H.
dc.date.accessioned2019-05-31T18:28:37Z
dc.date.available2020-07-01T17:47:46Zen
dc.date.issued2019-05
dc.identifier.citationStolz, Andrew; Navarro, Victor; Hayashi, Paul H.; Fontana, Robert J.; Barnhart, Huiman X.; Gu, Jiezhun; Chalasani, Naga P.; Vega, Maricruz M.; Bonkovsky, Herbert L.; Seeff, Leonard B.; Serrano, Jose; Avula, Bharathi; Khan, Ikhlas A.; Cirulli, Elizabeth T.; Kleiner, David E.; Hoofnagle, Jay H. (2019). "Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors." Alimentary Pharmacology & Therapeutics 49(9): 1195-1204.
dc.identifier.issn0269-2813
dc.identifier.issn1365-2036
dc.identifier.urihttps://hdl.handle.net/2027.42/149370
dc.publisherWiley Periodicals, Inc.
dc.titleSevere and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/149370/1/apt15211_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/149370/2/apt15211.pdf
dc.identifier.doi10.1111/apt.15211
dc.identifier.sourceAlimentary Pharmacology & Therapeutics
dc.identifier.citedreferenceRobles‐Diaz M, Gonzalez‐Jimenez A, Medina‐Caliz I, et al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol Ther. 2015; 41: 116 ‐ 125.
dc.identifier.citedreferenceBarceloux DG, Palmer RB. Anabolic‐androgenic steroids. Dis Mon. 2013; 59: 226 ‐ 248.
dc.identifier.citedreferenceNational Library of Medicine. Anabolic Steroids. https://livertox.nih.gov/AndrogenicSteroids.html Accessed October 1, 2018.
dc.identifier.citedreferenceVelazquez I, Alter BP. Androgens and liver tumors: Fanconi’s anemia and non‐Fanconi’s conditions. Am J Hematol. 2004; 77: 257 ‐ 267.
dc.identifier.citedreferencePope HG Jr, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic‐androgenic steroid use and dependence in Americans: current best estimates. Am J Addict. 2014; 23: 371 ‐ 377.
dc.identifier.citedreferenceKanayama G, Pope HG Jr. History and epidemiology of anabolic androgens in athletes and non‐athletes. Mol Cell Endocrinol. 2018; 464: 4 ‐ 13.
dc.identifier.citedreferenceEl Sherrif Y, Potts JR, Howard MR, et al. Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations? Liver Int. 2013; 33: 1266 ‐ 1270.
dc.identifier.citedreferenceLiebe R, Krawczyk M, Raszeja‐Wyszomirska J, et al. Heterozygous inactivation of the nuclear receptor PXR/NR1I2 in a patient with anabolic steroid‐induced intrahepatic cholestasis. Hepat Mon. 2016; 16: e35953.
dc.identifier.citedreferenceChalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 Patients with drug‐induced liver injury: the DILIN prospective study. Gastroenterology. 2015; 148: 1340 ‐ 1352 e1347.
dc.identifier.citedreferenceFontana RJ, Watkins PB, Bonkovsky HL, et al. Drug‐induced liver injury network (DILIN) prospective study. Drug Saf. 2009; 32: 55 ‐ 68.
dc.identifier.citedreferenceNavarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug‐Induced Liver Injury Network. Hepatology. 2014; 60: 1399 ‐ 1408.
dc.identifier.citedreferenceHayashi PH, Barnhart HX, Fontana RJ, et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug‐Induced Liver Injury Network (DILIN). Liver Int. 2014; 35: 1623 ‐ 1632.
dc.identifier.citedreferenceKleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug‐induced liver injury: systematic evaluation and clinical associations. Hepatology. 2013; 59: 661 ‐ 670.
dc.identifier.citedreferenceJacquemin E. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol. 2012; 36 ( Suppl. 1 ): S26 ‐ S35.
dc.identifier.citedreferenceDakhoul L, Ghabril M, Gu J, et al. Heavy consumption of alcohol is not associated with worse outcomes in patients with idiosyncratic drug‐induced liver injury compared to non‐drinkers. Clin Gastroenterol Hepatol. 2018; 16: 722 ‐ 729 e722.
dc.identifier.citedreferenceMedina‐Caliz I, Garcia‐Cortes M, Gonzalez‐Jimenez A, et al. Herbal and dietary supplement‐induced liver injuries in the Spanish DILI registry. Clin Gastroenterol Hepatol. 2018; 16: 1495 ‐ 1502.
dc.identifier.citedreferenceLek M, Karczewski KJ, Minikel EV, et al. Analysis of protein‐coding genetic variation in 60,706 humans. Nature. 2016; 536: 285 ‐ 291.
dc.identifier.citedreferenceAdzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen‐2. Current protocols in human genetics/editorial board, Jonathan L Haines [et al.]. 2013; Chapter 7: Unit7 20.
dc.identifier.citedreferenceLang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug‐induced liver injury. Pharmacogenet Genomics. 2007; 17: 47 ‐ 60.
dc.identifier.citedreferenceSchaffner F, Popper H, Chesrow E. Cholestasis produced by the administration of norethandrolone. Am J Med. 1959; 26: 249 ‐ 254.
dc.identifier.citedreferenceNathwani RA, Kumar SR, Reynolds TB, Kaplowitz N. Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. Am J Gastroenterol. 2005; 100: 295 ‐ 298.
dc.identifier.citedreferenceJurate K, Rimantas Z, Jolanta S, Vladas G, Limas K. Sensitivity and specificity of biochemical tests for diagnosis of intrahepatic cholestasis of pregnancy. Ann Hepatol. 2017; 16: 569 ‐ 573.
dc.identifier.citedreferenceStimac D, Milic S, Dintinjana RD, Kovac D, Ristic S. Androgenic/Anabolic steroid‐induced toxic hepatitis. J Clin Gastroenterol. 2002; 35: 350 ‐ 352.
dc.identifier.citedreferenceAnawalt BD. Detection of anabolic androgenic steroid use by elite athletes and by members of the general public. Mol Cell Endocrinol. 2018; 464: 21 ‐ 27.
dc.identifier.citedreferenceNieschlag E, Vorona E. Mechanisms in endocrinology: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. Eur J Endocrinol. 2015; 173: R47 ‐ R58.
dc.identifier.citedreferenceShah NL, Zacharias I, Khettry U, Afdhal N, Gordon FD. Methasteron‐associated cholestatic liver injury: clinicopathologic findings in 5 cases. Clin Gastroenterol Hepatol. 2008; 6: 255 ‐ 258.
dc.identifier.citedreferenceAlkhunaizi AM, ElTigani MA, Rabah RS, Nasr SH. Acute bile nephropathy secondary to anabolic steroids. Clin Nephrol. 2016; 85: 121 ‐ 126.
dc.identifier.citedreferenceBonkovsky HL, Kleiner DE, Gu J, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017; 65: 1267 ‐ 1277.
dc.identifier.citedreferenceBoyer JL. Bile formation and secretion. Compr Physiol. 2013; 3: 1035 ‐ 1078.
dc.identifier.citedreferenceAbbate V, Kicman AT, Evans‐Brown M, et al. Anabolic steroids detected in bodybuilding dietary supplements – a significant risk to public health. Drug Test Anal. 2015; 7: 609 ‐ 618.
dc.identifier.citedreferenceShahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic‐androgenic steroids. Clin Ther. 2001; 23: 1355 ‐ 1390.
dc.identifier.citedreferenceBagatell CJ, Bremner WJ. Androgens in men–uses and abuses. N Engl J Med. 1996; 334: 707 ‐ 714.
dc.identifier.citedreferenceIshak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis. 1987; 7: 230 ‐ 236.
dc.identifier.citedreferenceBagheri SA, Boyer JL. Peliosis hepatis associated with androgenic‐anabolic steroid therapy. A severe form of hepatic injury. Ann Intern Med. 1974; 81: 610 ‐ 618.
dc.identifier.citedreferenceSoe KL, Soe M, Gluud C. Liver pathology associated with the use of anabolic‐androgenic steroids. Liver. 1992; 12: 73 ‐ 79.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt15211_am.pdf
Size:
284.1KB
Format:
PDF
View/Open
Name:
apt15211.pdf
Size:
944.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.